key: cord-0774955-agxm1w54 authors: Avdeev, Sergey N.; Pozdnakova, Anna A.; Gaynitdinova, Viliya V.; Chikina, Svetlana Yu; Vlasenko, Anna E. title: Asthma in older adults with severe COVID-19: clinical outcomes and predictors of mortality. date: 2021-10-17 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2021.10.016 sha: 809c4a9cfc7537b3d8adf9e2b8c1558d9e204303 doc_id: 774955 cord_uid: agxm1w54 nan The authors declare that they have no relevant conflicts of interest. Contributorship Statement: All authors were involved in the assessment and treatment of the patient, and in the writing and correction of the manuscript. The study was approved by the Medical Ethical Committee of Sechenov Moscow Medical University (protocol number 08-20/5). To date, numerous studies have examined the relationship between COVID-19 and asthma; however, the impact of asthma on COVID-19-associated outcomes remains controversial and not fully understood [1] [2] [3] . It is possible that these contradictions can be explained in terms of asthma heterogeneity. There is data to suggest that asthma in older adults is phenotypically different from that in young patients, particularly when physiological changes associated with the aging process are taken into account 4 . Since old age is a well-known factor of a poor prognosis in COVID-19 5 , it is of great interest to study the course of COVID-19 in older patients with asthma. This observational study was conducted in the Pulmonology Department of a universityaffiliated hospital between May 12, 2020, and December 27, 2020. As this was a retrospective study, the requirement for informed consent was waived. We enrolled patients over 65 years old with physician diagnosed asthma admitted with SARS-CoV-2 infection confirmed by real-time polymerase chain reaction, radiological findings compatible with severe COVID-19 pneumonia, and SpO 2 at admission <92% (on room air). The exclusion criteria were non-asthma chronic lung diseases. The diagnostic criteria of allergic asthma were those of the GINA guidelines: an exposure to the allergen induces or aggravates the symptoms, and the skin prick test and serum specific IgE test show positive responses to at least one allergen 6 . Demographic, clinical, and laboratory data was recorded at admission. We recorded the Charlson Comorbidity Index (CCI), which calculates the score for comorbidities according to the relative risks of 19 major diseases, including ischemic heart disease, diabetes, and hypertension. We also analyzed the outcomes of COVID-19, such as a transfer to the intensive care unit (ICU), need for non-invasive and invasive mechanical ventilation, and 28-day mortality. The objectives of this study were: (1) to investigate the influence of asthma in older adults on COVID-19 outcomes, and (2) to identify predictors of in-hospital mortality of older patients with asthma and COVID-19. The Cox proportional hazard models were used to estimate the association between asthma and in-hospital mortality; the models were adjusted for age, sex, and comorbidities. Of the 2,435 patients hospitalized with COVID-19 infection, 69 patients met the necessary diagnostic criteria (2.8%). Baseline characteristics of the study population are shown in Table 1 . Most patients had a non-allergic asthma phenotype (44 patients, 63.8%) and multiple comorbidities (the median CCI was 5.3). Nineteen of included patients (27.5%) were receiving GINA step 4-5 therapies; 12 patients (17.4%) and 4 patients (5.8%) were treated before admission with maintenance oral steroids and biologic therapy ((omalizumab (n=2), mepolizumab (n=2)), respectively. During hospitalization, all patients received the standard therapy including prophylactic enoxaparin, intravenous dexamethasone, and tocilizumab. Supplemental oxygen was administered in all patients (100%), non-invasive ventilation and invasive mechanical ventilation were used in 6 (8.6%) and 7(10.1%) patients, respectively. Twelve patients (17.3%) were transferred to the ICU, and the 28-day mortality rate was 13%(9 patients). All patients who died had non-allergic asthma. There was a significant difference in the proportion of patients with severe asthma among deceased and surviving patients (56% vs 13%; p=0.01). Patients who died from COVID-19 used maintenance oral steroids more often than survivors (44% vs 13%, p=0.04). Patients who died had a significantly higher CCI, higher body temperature at admission, higher respiratory rate, and a higher baseline blood neutrophil count, neutrophil/lymphocyte ratio, fibrinogen, lactate dehydrogenase, glucose levels, and C-reactive protein at Day 5 compared to survivors. The Cox regression analysis identified the following variables predicting poor outcomes: CCI (risk ratio (RR) 1 In a recently published study, Eggert and colleagues showed that among asthmatics positive for SARS-CoV-2, the allergic asthma phenotype was associated with a reduced risk of hospital admissions, meaning that certain phenotypes of asthma may be protective 7 retrospective study demonstrated that in patients with asthma pre-existing blood eosinophilia greater than or equal to 150 cells/mL was protective from COVID-19-associated admission 9 . In our cohort of older adults with asthma, we were unable to show differences in eosinophilia levels between deceased and surviving patients. However, it cannot be ruled out that the blood eosinophil counts did not differ significantly due to the outpatient and inpatient use of systemic steroids. In our study therapy with maintenance oral steroids in older adults with asthma was a risk factor for poor prognosis. Similar data was presented in a recent study by Adir et al. who also showed that systemic steroid use was significantly associated with an increased risk of severe COVID-19 and all-cause mortality 10 . In contrast to the study by Adir et al., in our study, all patients had severe COVID-19 and all received intravenous dexamethasone during hospitalization. Despite this, a chronic use of steroids turned out to be a factor of poor prognosis. Our study has several limitations. It was a retrospective study performed in a single center, and statistical analysis and interpretation of our study results are further limited by its relatively small sample size. Therefore, our study provided evidence that non-allergic asthma phenotype, asthma severity, systemic steroid use, and comorbidities may be risk factors for poor outcomes in older patients with asthma and severe COVID-19. However, further large cohort studies are needed to examine the effect of asthma severity and phenotypes on COVID-19 outcomes in older adults. COVID-19 in severe asthma network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments Asthma is associated with increased risk of intubation but not hospitalization or death in coronavirus disease 2019 Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19 Asthma in elderly is characterized by increased sputum neutrophils, lower airway caliber variability and air trapping Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19 Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2 Eosinophilia in asthma patients is protective against severe COVID-19 illness COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence *The highest temperature during the day was recorded. Continuous variables are presented as median value Charlson comorbidity index; SpO 2 , oxygen saturation; FiO 2 , inspired oxygen fraction; C-reactive protein Mann-Whitney test was used